NCT02172144View on ClinicalTrials.gov

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2007

Conditions
Healthy
Interventions
DRUG

BI 1744 CL solution for inhalation

DRUG

Placebo matching BI 1744 CL

DRUG

Moxifloxacin (Avalox®)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY